BioNTech SE (BNTX) Assets (2018 - 2025)
BioNTech SE (BNTX) posted Assets of $25.6 billion for Q4 2025, up 2.59% sequentially from $24.9 billion in Q3 2025, and up 6.32% YoY from $24.1 billion in Q4 2024.
BioNTech SE (BNTX) Assets (2018 - 2025) Analysis & Trends
BioNTech SE has reported Assets for 8 years, with the latest figure at $25.6 billion in Q4 2025.
- Quarterly Assets rose 6.32% year-over-year to $25.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.6 billion (up 6.32% YoY) and the FY2025 annual result came in at $24.8 billion, up 3.19% from the prior year.
- Assets climbed to $25.6 billion in Q4 2025 per BNTX's latest filing, from $24.9 billion in the prior quarter.
- Over five years, Assets peaked at $25.6 billion in Q4 2025 and troughed at $5.1 billion in Q1 2021.
- A 5-year average of $21.7 billion and a median of $23.8 billion in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2021 and 2025: Assets jumped 927.56% in 2021, then fell 7.85% in 2025.
- Over 5 years, Assets stood at $18.1 billion in 2021, then jumped by 31.15% to $23.8 billion in 2022, then grew by 4.22% to $24.8 billion in 2023, then slipped by 2.74% to $24.1 billion in 2024, then grew by 6.32% to $25.6 billion in 2025.
- According to Business Quant data, Assets over the past three periods registered $25.6 billion, $24.9 billion, and $24.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Roivant Sciences | 26.33 Bn | 26.33 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.60 Bn |
| Sep 30, 2025 | 24.95 Bn |
| Jun 30, 2025 | 24.49 Bn |
| Mar 31, 2025 | 22.28 Bn |
| Dec 31, 2024 | 24.08 Bn |
| Sep 30, 2024 | 24.60 Bn |
| Jun 30, 2024 | 23.95 Bn |
| Mar 31, 2024 | 24.18 Bn |
| Dec 31, 2023 | 24.75 Bn |
| Sep 30, 2023 | 24.17 Bn |
| Jun 30, 2023 | 24.20 Bn |
| Mar 31, 2023 | 23.70 Bn |
| Dec 31, 2022 | 23.75 Bn |
| Sep 30, 2022 | 22.85 Bn |
| Jun 30, 2022 | 22.57 Bn |
| Mar 31, 2022 | 22.78 Bn |
| Dec 31, 2021 | 18.11 Bn |
| Sep 30, 2021 | 16.78 Bn |
| Jun 30, 2021 | 11.02 Bn |
| Mar 31, 2021 | 5.07 Bn |